Sanofi (SNY) Competitors $48.61 -0.73 (-1.48%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$48.40 -0.20 (-0.42%) As of 07/11/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY vs. NVO, NVS, AZN, GSK, TAK, ARGX, BNTX, ONC, TEVA, and INSMShould you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novo Nordisk A/S (NVO), Novartis (NVS), AstraZeneca (AZN), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), BeOne Medicines (ONC), Teva Pharmaceutical Industries (TEVA), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry. Sanofi vs. Its Competitors Novo Nordisk A/S Novartis AstraZeneca GSK Takeda Pharmaceutical argenex BioNTech BeOne Medicines Teva Pharmaceutical Industries Insmed Sanofi (NASDAQ:SNY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Do institutionals & insiders believe in SNY or NVO? 14.0% of Sanofi shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is SNY or NVO a better dividend stock? Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Novo Nordisk A/S pays an annual dividend of $1.64 per share and has a dividend yield of 2.4%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 48.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Which has better valuation & earnings, SNY or NVO? Novo Nordisk A/S has lower revenue, but higher earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$44.46B2.68$6.02B$2.8017.36Novo Nordisk A/S$42.12B7.31$14.64B$3.3820.39 Do analysts rate SNY or NVO? Sanofi presently has a consensus target price of $61.50, suggesting a potential upside of 26.52%. Novo Nordisk A/S has a consensus target price of $112.00, suggesting a potential upside of 62.48%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Sanofi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 3 Strong Buy rating(s) 3.11Novo Nordisk A/S 2 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.27 Does the media favor SNY or NVO? In the previous week, Sanofi had 4 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 46 mentions for Sanofi and 42 mentions for Novo Nordisk A/S. Novo Nordisk A/S's average media sentiment score of 1.16 beat Sanofi's score of 0.84 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 18 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 33 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is SNY or NVO more profitable? Novo Nordisk A/S has a net margin of 34.52% compared to Sanofi's net margin of 14.56%. Novo Nordisk A/S's return on equity of 80.94% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi14.56% 17.15% 9.80% Novo Nordisk A/S 34.52%80.94%24.23% Which has more volatility & risk, SNY or NVO? Sanofi has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. SummaryNovo Nordisk A/S beats Sanofi on 11 of the 19 factors compared between the two stocks. Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNY vs. The Competition Export to ExcelMetricSanofiLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.21B$254.33B$5.56B$9.11BDividend Yield3.29%2.83%5.06%4.01%P/E Ratio17.3627.9128.2620.26Price / Sales2.685.00437.10166.10Price / Cash9.1213.9337.1257.67Price / Book1.4617.848.045.49Net Income$6.02B$8.49B$3.19B$250.45M7 Day Performance-0.56%0.73%3.62%4.79%1 Month Performance-2.13%-2.20%5.98%9.59%1 Year Performance-5.30%-5.29%29.39%16.41% Sanofi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYSanofi4.14 of 5 stars$48.61-1.5%$61.50+26.5%-5.3%$119.21B$44.46B17.3682,878Trending NewsAnalyst RevisionNVONovo Nordisk A/S4.633 of 5 stars$69.31+0.2%$112.00+61.6%-51.5%$309.47B$42.12B20.5177,349Positive NewsNVSNovartis1.5475 of 5 stars$122.11+0.2%$123.67+1.3%+8.3%$257.95B$50.32B19.0875,883Upcoming EarningsAZNAstraZeneca3.7594 of 5 stars$69.63+0.3%$85.00+22.1%-10.2%$215.94B$54.07B27.9694,300Positive NewsAnalyst ForecastGSKGSK1.7895 of 5 stars$38.21+0.1%$37.38-2.2%-2.2%$78.23B$40.10B19.7068,629Gap DownTAKTakeda Pharmaceutical2.1186 of 5 stars$15.07-1.8%N/A+9.2%$47.95B$30.09B68.5047,455Positive NewsARGXargenex4.4131 of 5 stars$546.04+0.5%$728.06+33.3%+20.1%$33.34B$2.25B33.691,599Analyst UpgradeBNTXBioNTech1.6374 of 5 stars$110.05+0.0%$137.86+25.3%+32.9%$26.45B$2.98B-32.376,772News CoverageAnalyst ForecastONCBeOne Medicines3.4372 of 5 stars$240.99-1.8%$320.67+33.1%N/A$26.41B$4.18B-64.7811,000Trending NewsAnalyst DowngradeInsider TradeTEVATeva Pharmaceutical Industries4.1226 of 5 stars$16.84-1.0%$24.13+43.3%-5.2%$19.31B$16.54B-14.6436,830INSMInsmed4.3703 of 5 stars$96.95-0.9%$106.80+10.2%+28.0%$18.39B$363.71M-16.291,271Positive NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies NVO Alternatives NVS Alternatives AZN Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives BNTX Alternatives ONC Alternatives TEVA Alternatives INSM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNY) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.